New drug combo aims to tame Graft-Versus-Host disease
NCT ID NCT07340723
First seen Jan 17, 2026 · Last updated May 04, 2026 · Updated 8 times
Summary
This study tests whether adding the drug ruxolitinib to standard steroids works better than steroids alone for treating grade II acute graft-versus-host disease (GVHD), a common complication after a stem cell transplant. About 168 adults who have had a stem cell transplant for blood cancer and develop GVHD within 100 days will take part. The main goal is to see if the combination leads to a complete or partial response by day 28.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STEM CELL TRANSPLANT COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.